Suppr超能文献

r207910揭示的结核分枝杆菌在豚鼠结核病模型中的持续存在位置。

Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

作者信息

Lenaerts Anne J, Hoff Donald, Aly Sahar, Ehlers Stefan, Andries Koen, Cantarero Luis, Orme Ian M, Basaraba Randall J

机构信息

Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA.

出版信息

Antimicrob Agents Chemother. 2007 Sep;51(9):3338-45. doi: 10.1128/AAC.00276-07. Epub 2007 May 21.

Abstract

The lengthy chemotherapy of tuberculosis reflects the ability of a small subpopulation of Mycobacterium tuberculosis bacteria to persist in infected individuals. To date, the exact location of these persisting bacteria is not known. Lung lesions in guinea pigs infected with M. tuberculosis have striking similarities, such as necrosis, mineralization, and hypoxia, to natural infections in humans. Guinea pigs develop necrotic primary lesions after aerosol infection that differ in their morphology compared to secondary lesions resulting from hematogenous dissemination. In infected guinea pigs conventional therapy for tuberculosis during 6 weeks reduced the bacterial load by 1.7 logs in the lungs and, although this completely reversed lung inflammation associated with secondary lesions, the primary granulomas remained largely unaffected. Treatment of animals with the experimental drug R207910 (TMC207) for 6 weeks was highly effective with almost complete eradication of the bacteria throughout both the primary and the secondary lesions. Most importantly, the few remnants of acid-fast bacilli remaining after R207910 treatment were to be found extracellular, in a microenvironment of residual primary lesion necrosis with incomplete dystrophic calcification. This zone of the primary granuloma is hypoxic and is morphologically similar to what has been described for human lung lesions. These results show that this acellular rim may, therefore, be a primary location of persisting bacilli withstanding drug treatment.

摘要

结核病的长期化疗反映了一小部分结核分枝杆菌在受感染个体中持续存在的能力。迄今为止,这些持续存在的细菌的确切位置尚不清楚。感染结核分枝杆菌的豚鼠肺部病变与人类自然感染有显著相似之处,如坏死、矿化和缺氧。豚鼠经气溶胶感染后会形成坏死性原发性病变,其形态与血行播散导致的继发性病变不同。在感染的豚鼠中,为期6周的常规结核病治疗使肺部细菌载量降低了1.7个对数,尽管这完全逆转了与继发性病变相关的肺部炎症,但原发性肉芽肿基本未受影响。用实验药物R207910(TMC207)对动物进行6周治疗非常有效,几乎完全根除了原发性和继发性病变中的细菌。最重要的是,在R207910治疗后残留的少数抗酸杆菌残留在细胞外,处于原发性病变坏死残留且营养不良性钙化不完全的微环境中。原发性肉芽肿的这个区域缺氧,形态上与人类肺部病变的描述相似。因此,这些结果表明,这个无细胞边缘可能是持续存在的杆菌耐受药物治疗的主要位置。

相似文献

1
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.
Antimicrob Agents Chemother. 2007 Sep;51(9):3338-45. doi: 10.1128/AAC.00276-07. Epub 2007 May 21.
2
Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs.
Antimicrob Agents Chemother. 2011 Jan;55(1):124-31. doi: 10.1128/AAC.00978-10. Epub 2010 Oct 11.
3
Delamanid Kills Dormant Mycobacteria and in a Guinea Pig Model of Tuberculosis.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02402-16. Print 2017 Jun.
4
Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2008 Nov;52(11):4137-40. doi: 10.1128/AAC.00196-08. Epub 2008 Aug 11.
5
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
Antimicrob Agents Chemother. 2006 Nov;50(11):3543-7. doi: 10.1128/AAC.00766-06. Epub 2006 Sep 5.
6
Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.
Antimicrob Agents Chemother. 2008 Oct;52(10):3568-72. doi: 10.1128/AAC.00566-08. Epub 2008 Jul 21.
7
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
J Antimicrob Chemother. 2003 Dec;52(6):981-6. doi: 10.1093/jac/dkg477. Epub 2003 Nov 12.
10
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
Antimicrob Agents Chemother. 2011 Dec;55(12):5485-92. doi: 10.1128/AAC.05293-11. Epub 2011 Sep 19.

引用本文的文献

1
Model systems to study infections: an overview of scientific potential and impediments.
Front Cell Infect Microbiol. 2025 May 8;15:1572547. doi: 10.3389/fcimb.2025.1572547. eCollection 2025.
5
Mycobacteria develop biofilms on airway epithelial cells and promote mucosal barrier disruption.
iScience. 2024 Sep 27;27(11):111063. doi: 10.1016/j.isci.2024.111063. eCollection 2024 Nov 15.
6
Molecular and microbiological methods for the identification of nonreplicating Mycobacterium tuberculosis.
PLoS Pathog. 2024 Oct 9;20(10):e1012595. doi: 10.1371/journal.ppat.1012595. eCollection 2024 Oct.
7
Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments.
Int J Mol Sci. 2024 Jul 16;25(14):7771. doi: 10.3390/ijms25147771.
8
Biofilms: Immune Responses, Role in TB Pathology, and Potential Treatment.
Immunotargets Ther. 2024 Jul 3;13:335-342. doi: 10.2147/ITT.S455744. eCollection 2024.
10
Mycobacterial biofilms: A therapeutic target against bacterial persistence and generation of antibiotic resistance.
Heliyon. 2024 May 29;10(11):e32003. doi: 10.1016/j.heliyon.2024.e32003. eCollection 2024 Jun 15.

本文引用的文献

1
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2007 Apr;51(4):1380-5. doi: 10.1128/AAC.00055-06. Epub 2007 Jan 8.
2
Is adipose tissue a place for Mycobacterium tuberculosis persistence?
PLoS One. 2006 Dec 20;1(1):e43. doi: 10.1371/journal.pone.0000043.
3
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
Antimicrob Agents Chemother. 2007 Mar;51(3):1011-5. doi: 10.1128/AAC.00898-06. Epub 2006 Dec 18.
4
Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice.
J Pathol. 2006 Nov;210(3):298-305. doi: 10.1002/path.2055.
5
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
Antimicrob Agents Chemother. 2006 Nov;50(11):3543-7. doi: 10.1128/AAC.00766-06. Epub 2006 Sep 5.
8
Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2006 Apr;50(4):1245-50. doi: 10.1128/AAC.50.4.1245-1250.2006.
9
Lymphadenitis as a major element of disease in the guinea pig model of tuberculosis.
Tuberculosis (Edinb). 2006 Sep;86(5):386-94. doi: 10.1016/j.tube.2005.11.003. Epub 2006 Feb 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验